The nation of Zimbabwe has turned down a major American healthcare agreement valued at $367m (£272m) over five years over Washington's request for sensitive data.
This rejection was revealed after a government memo from December was leaked, indicating that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government spokesperson has since clarified that the US was requesting genetic material for scientific study and commercial purposes but was not willing to guarantee the benefits from future treatments.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged further negotiations to secure a deal suitable to all parties so the nation's vital HIV programme can be sustained.
Broader Background
This rejection follows a similar case in Kenya, where a court halted a similar deal with the US after concerns were raised about the safety of citizens' medical information.
Since resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral deals to enhance openness and responsibility.
According to reports, Sixteen African countries have so far signed similar agreements, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data indefinitely, with no corresponding promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"In essence, our nation would provide the raw materials for medical research without any certainty that the resulting innovations would be available to our people if a new pandemic emerge."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining frameworks already set up through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential pandemics.
"This system is intended to ensure that when a country contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome further discussions with our American counterparts on how future collaboration might be structured in a way that respects the sovereignty and dignity of both nations."
Medical Community Reaction
Medical experts expressed it understood the official position, but urged that negotiations must proceed given that much of the country's HIV programmes were funded by foreign aid.
"Where technical issues arise, including those involving information security or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," it commented.
The situation underscores the ongoing challenges between accepting vital international aid and protecting local interests in an ever more interconnected world.